Selective TPK1 Inhibitor Avoiding CYP2D6 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's lack effective inhibitors of tau protein kinase 1 (TPK1) that do not interfere with cytochrome P450 2D6, leading to potential drug interactions and side effects.
Innovation Solution
A novel compound represented by formula (I) is developed, which effectively inhibits TPK1 activity without inhibiting cytochrome P450 2D6, offering improved in vivo activity and reduced risk of drug interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TPK1 inhibitors are used to treat neurodegenerative diseases, then TPK1 activity is inhibited, but cytochrome P450 2D6 is also inhibited causing drug interactions and side effects
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (formula I) that confer selective affinity for TPK1 over cytochrome P450 2D6. The molecular structure incorporates specific functional groups and spatial arrangement that enable preferential binding to TPK1's active site while avoiding the active site of cytochrome P450 2D6, thus achieving localized therapeutic action without off-target effects
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the inhibitor compound including substituent types (R1-R6 groups), stereochemistry ((2S) configuration), and molecular weight. These parameter optimizations were performed to enhance selectivity for TPK1 while reducing binding affinity to cytochrome P450 2D6, thereby resolving the contradiction between therapeutic effectiveness and drug interaction risk
2Object-affected harmful factors
If current TPK1 inhibitor treatments are administered, then neurotoxicity is reduced, but potential side effects and drug interactions increase
Solution Approach 1:
The patent converts the potential harm of off-target inhibition into a benefit by designing a molecule that specifically targets TPK1 while explicitly avoiding cytochrome P450 2D6 inhibition. The compound structure is engineered to exploit the unique features of TPK1's active site, transforming what would normally be a source of drug interactions into a therapeutic advantage through high selectivity
Solution Approach 2:
The patent introduces a selective inhibitor compound as an intermediary substance that mediates between the therapeutic goal (TPK1 inhibition) and the avoidance of harmful effects (cytochrome P450 2D6 inhibition). This intermediary molecule acts as a bridge that achieves the desired therapeutic effect while blocking the pathway to off-target side effects through its selective binding properties
Data Source
AI summary
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).